JP Morgan Chase’s Karyopharm Therapeutics KPTI Stock Holding History

JP Morgan Chase’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$63.5K	Buy	+6,300	New	+$54.6K	﹤0.01%	6324
2025 Q4	–	Sell	-414,300	Closed	-$2.71M	–	7605
2025 Q3	$2.71M	Buy	414,300 +220,400	+114%	+$1.19M	﹤0.01%	3852
2025 Q2	$836K	Buy	193,900 +184,400	+1,941%	+$905K	﹤0.01%	4494
2025 Q1	$35.5K	Buy	+9,500	New	+$81.1K	﹤0.01%	5983
2022 Q2	–	Sell	-8,620	Closed	-$953K	–	6689
2022 Q1	$953K	Buy	+8,620	New	+$1.07M	﹤0.01%	4310
2020 Q3	–	Sell	-5,407	Closed	-$1.54M	–	5629
2020 Q2	$1.54M	Sell	5,407 -5,260	-49%	-$1.56M	﹤0.01%	3270
2020 Q1	$3.07M	Buy	+10,667	New	+$2.94M	﹤0.01%	2643
2019 Q2	–	Sell	-16,667	Closed	-$1.46M	–	5886
2019 Q1	$1.46M	Buy	+16,667	New	+$1.85M	﹤0.01%	3555

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

JP Morgan Chase's KPTI Position: Q2 2026 in Review

JP Morgan Chase increased its Karyopharm Therapeutics (KPTI) stake by 43,978% in Q2 2026, buying an estimated $1.8M and bringing the position to 207,609 shares worth $2.09M. The position accounts for ﹤0.01% of the portfolio, ranked #4139.

JP Morgan Chase first reported a position in KPTI in Q4 2013 and has held it in 51 quarters since. The position peaked at $6.85M in Q4 2019. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

JP Morgan Chase held 207,609 shares of Karyopharm Therapeutics worth $2.09M as of Q2 2026.
JP Morgan Chase bought 207,138 Karyopharm Therapeutics shares in Q2 2026, an estimated $1.8M.
Karyopharm Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4139 holding.
JP Morgan Chase first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 51 quarters since.
JP Morgan Chase's Karyopharm Therapeutics position peaked at $6.85M in Q4 2019.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.